Where can I get compounded Compounded Tirzepatide 17 mg (Sublingual)?

Compounded Tirzepatide 17 mg (Sublingual) is available at compounding pharmacies on the SlimionRX network, including Benbrook pharmacy .

Compounded Tirzepatide 17 mg (Sublingual) 17.14 mg / 0.5 mL — Compounded Sublingual Liquid Patient Monograph

Patient education monograph for Compounded Tirzepatide 17 mg (Sublingual) (17.14 mg / 0.5 mL), a compounded sublingual liquid. Learn how it works, how to use it, possible side effects, and find a licensed compounding pharmacy near you.

What is Compounded Tirzepatide 17 mg (Sublingual)?

This compounded preparation contains tirzepatide 17.14 mg per 0.5 mL in a sublingual liquid base, prepared by a licensed compounding pharmacy pursuant to a valid individual patient prescription. This high-dose formulation is designed for patients who have completed full titration and require maximum-range maintenance dosing within a medically supervised weight management program. Compounded tirzepatide is not an FDA-approved product. Formula developed in partnership with Richie's Specialty Pharmacy.

How does Compounded Tirzepatide 17 mg (Sublingual) work?

Tirzepatide's dual GIP/GLP-1 receptor agonism drives potent and sustained reductions in appetite, caloric intake, and body weight. At 17.14 mg — the highest dose in this compounded series — GIP and GLP-1 receptor engagement is maximal, providing the strongest available appetite suppression and metabolic benefit within this compound class. The sublingual preparation delivers the weekly dose through oral mucosal absorption for patients who have demonstrated tolerance through progressive dose escalation.

How to use Compounded Tirzepatide 17 mg (Sublingual)

Administer under the tongue once weekly exactly as directed by your prescriber. Hold the preparation under the tongue for at least 60 seconds before swallowing. Do not eat, drink, or rinse your mouth for at least 10 minutes after administration. Administer consistently on the same day each week. Do not adjust the dose independently — this is the maximum dose in this compound series.

Compounded Tirzepatide 17 mg (Sublingual) side effects

GI side effects (nausea, vomiting, diarrhea, constipation, abdominal discomfort) are common at this dose and may be more prominent, particularly if recently escalated. Decreased appetite is a therapeutic effect. Fatigue, dizziness, and gallbladder-related symptoms should be monitored. Report any severe abdominal pain, persistent vomiting, rapid heart rate, or signs of pancreatitis or gallbladder disease to your prescriber without delay.

Drug interactions with Compounded Tirzepatide 17 mg (Sublingual)

Tirzepatide significantly slows gastric emptying — consider timing of co-administered oral medications, particularly those with narrow therapeutic windows. Insulin and sulfonylurea concurrent use increases hypoglycemia risk. Disclose all current medications, including supplements and OTC drugs, to your prescriber. Blood pressure medications and anticoagulants may require additional monitoring during weight loss therapy.

How to store Compounded Tirzepatide 17 mg (Sublingual)

Refrigerate at 36°F–46°F (2°C–8°C). Do not freeze. Protect from light. Keep tightly closed. Use within the beyond-use date printed on the pharmacy label. Discard if the solution appears cloudy, discolored, or contains particles.

Precautions for Compounded Tirzepatide 17 mg (Sublingual)

Contraindicated in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia type 2. This is the highest dose in the series — use only under close and active prescriber supervision. Gallbladder disease associated with rapid weight loss is a meaningful risk. Do not use during pregnancy. Keep out of reach of children.

Where to get compounded Compounded Tirzepatide 17 mg (Sublingual)

Compounded Tirzepatide 17 mg (Sublingual) is available through licensed compounding pharmacies on the SlimionRX network:

Benbrook pharmacy — Benbrook, TX

Frequently Asked Questions — Compounded Tirzepatide 17 mg (Sublingual)

What is Compounded Tirzepatide 17 mg (Sublingual)?: This compounded preparation contains tirzepatide 17.14 mg per 0.5 mL in a sublingual liquid base, prepared by a licensed compounding pharmacy pursuant to a valid individual patient prescription. This high-dose formulation is designed for patients who have completed full titration and require maximum-range maintenance dosing within a medically supervised weight management program. Compounded tirzepatide is not an FDA-approved product. Formula developed in partnership with Richie's Specialty Pharm
How does Compounded Tirzepatide 17 mg (Sublingual) work?: Tirzepatide's dual GIP/GLP-1 receptor agonism drives potent and sustained reductions in appetite, caloric intake, and body weight. At 17.14 mg — the highest dose in this compounded series — GIP and GLP-1 receptor engagement is maximal, providing the strongest available appetite suppression and metabolic benefit within this compound class. The sublingual preparation delivers the weekly dose through oral mucosal absorption for patients who have demonstrated tolerance through progressive dose escal
How do I use Compounded Tirzepatide 17 mg (Sublingual)?: Administer under the tongue once weekly exactly as directed by your prescriber. Hold the preparation under the tongue for at least 60 seconds before swallowing. Do not eat, drink, or rinse your mouth for at least 10 minutes after administration. Administer consistently on the same day each week. Do not adjust the dose independently — this is the maximum dose in this compound series.
What are the side effects of Compounded Tirzepatide 17 mg (Sublingual)?: GI side effects (nausea, vomiting, diarrhea, constipation, abdominal discomfort) are common at this dose and may be more prominent, particularly if recently escalated. Decreased appetite is a therapeutic effect. Fatigue, dizziness, and gallbladder-related symptoms should be monitored. Report any severe abdominal pain, persistent vomiting, rapid heart rate, or signs of pancreatitis or gallbladder disease to your prescriber without delay.
Are there drug interactions with Compounded Tirzepatide 17 mg (Sublingual)?: Tirzepatide significantly slows gastric emptying — consider timing of co-administered oral medications, particularly those with narrow therapeutic windows. Insulin and sulfonylurea concurrent use increases hypoglycemia risk. Disclose all current medications, including supplements and OTC drugs, to your prescriber. Blood pressure medications and anticoagulants may require additional monitoring during weight loss therapy.
How should I store Compounded Tirzepatide 17 mg (Sublingual)?: Refrigerate at 36°F–46°F (2°C–8°C). Do not freeze. Protect from light. Keep tightly closed. Use within the beyond-use date printed on the pharmacy label. Discard if the solution appears cloudy, discolored, or contains particles.
What precautions should I know about Compounded Tirzepatide 17 mg (Sublingual)?: Contraindicated in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia type 2. This is the highest dose in the series — use only under close and active prescriber supervision. Gallbladder disease associated with rapid weight loss is a meaningful risk. Do not use during pregnancy. Keep out of reach of children.
Where can I get compounded Compounded Tirzepatide 17 mg (Sublingual)?: Compounded Tirzepatide 17 mg (Sublingual) is available at compounding pharmacies on the SlimionRX network, including Benbrook pharmacy .